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FBN1 = fibrillin1; HLA = human leukocyte antigen; IL = interleukin; PCR = polymerase chain reaction; SSc = systemic sclerosis; TGF-β = trans-
forming growth factor-β; TNF = tumour necrosis factor; tsk1 = tight skin 1 (mouse); UCD 200 = University of California at Davis line 200 (chicken).
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Introduction
Systemic sclerosis (SSc), also termed ‘scleroderma’, is a
multisystem connective tissue disease characterised by
excessive fibrosis, vascular abnormalities, and immune
dysfunction. There is a strong predominance of affected
females over males (3:1), and the peak age of onset is 30
to 50 years. There are two disease subtypes, defined on
the basis of the extent of skin involvement: limited cuta-
neous and diffuse cutaneous [1]. These two subtypes
have differing natural histories, prognoses, and autoanti-
body associations. Patients with limited cutaneous
disease have prominent vascular features, often with
severe digital ischaemia and, later on in their disease, pul-
monary arterial hypertension.
In recent years, there has been considerable interest in the
concept of SSc, similar to that in other rheumatic and
autoimmune diseases, as a multifactorial disease, possibly
triggered by environmental factors in a genetically predis-
posed host. A genetic predisposition to SSc is suggested
by the following: familial SSc (families with multiple cases,
although rare, have been reported); animal models; and
associations between SSc and polymorphisms in what is
now a sizable number of genes.
Familial systemic sclerosis
Recent large cohort studies from Australia and the USA
reported that SSc occurred in one or more first-degree
relatives in 1.4% [2] and 1.6% [3] of the families of
patients with SSc. These figures compare with an esti-
mated prevalence of SSc in the USA of 2.6 cases/10,000
(0.026%) [3]. Familial risk can be quantified as a recur-
rence rate (λ), and on the basis of these figures, λr (for
first-degree relatives) is 54. This is a high value in compari-
son with the values for many other complex diseases, and
the conclusion from these studies is that although the
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absolute risk for each family member is less than 1%, a
positive family history is the strongest risk factor yet identi-
fied for SSc. Comparison of concordance rates in
monozygotic and dizygotic twins can also be used to
quantify the genetic component of susceptibility, but in a
condition as rare as SSc, collecting sufficient twin pairs is
likely to be extremely difficult. Not surprisingly, therefore,
relatively few twin studies have been reported: De Keyser
et al. recently reported concordance for scleroderma in
two pairs of identical female twins — one pair with SSc,
the other pair with localised scleroderma [4]. 
Animal models
Two of the best-known animal models for SSc are the
tight skin 1 (tsk1) mouse and the University of California at
Davis line 200 (UCD 200) chicken. Of these two models,
only the UCD 200 chicken develops vascular injury [5].
The tsk1 mouse possesses a duplication within the
fibrillin1 (FBN1) gene [6], which encodes a glycoprotein
that is a major constituent of 10–12 nm microfibrils in the
extracellular matrix. The UCD 200 chickens show early
endothelial-cell apoptosis, followed by perivascular infiltra-
tion of mononuclear cells and collagen deposition [7].
Thus these animal models provide insight into how genetic
abnormalities that are presumably different can lead to a
fibrosing phenotype. Recently, Yamamoto et al. have
described a bleomycin-induced mouse model for sclero-
derma — certain strains of mouse (Ch3/He and B10.A)
were particularly susceptible to bleomycin-induced dermal
sclerosis, emphasising how genetic susceptibility and an
environmental trigger may both play a role in the patho-
genesis of SSc [8]. 
Disease associations
Over the past 10 years, the genetic basis of an ever-
increasing number of complex or multifactorial conditions
has been investigated through the approach of non-
parametric analysis of linkage in affected sibling-pair fami-
lies. Such studies screen the whole genome in search of
loci linked to disease. Hundreds of families are required
for adequate power and the approach is not likely to be
feasible for SSc except in an internationally coordinated
study. Such a study, in turn, could be complicated by
genetic heterogeneity across populations: a recognised
feature of SSc. The highest disease prevalence observed
to date was in a genetically isolated population of
Choctaw American Indians. This population offers a rare
opportunity to study large, extended pedigree(s) with
many affected individuals. With the exception of studies
in this population, all investigations of the genetic basis of
SSc have been disease-association studies, in which
allele or genotype frequencies of polymorphisms in
potential disease genes are compared in cases and con-
trols. This approach has advantages, but there are many
examples in the literature, in all diseases, of both false-
positive and false-negative results arising from poor study
design. Ideally, cases and controls should be well
matched, power calculations should be used to deter-
mine the appropriate number of samples to be analysed,
and positive associations should be replicated in inde-
pendent cohorts. Recent data suggest that the selection
of markers for association studies is critical, because old
assumptions about linkage disequilibrium do not neces-
sarily hold true [9].
The complex pathophysiology of SSc means that there are
a great many genes that are potential ‘culprits’, either
singly or, more likely, together, in driving the disease
process. Thus, genes involved in fibrosis, in vascular struc-
ture and function, and in autoimmunity all warrant investi-
gation. The genes discussed below are among those that
have already been examined in recent years.
Genes primarily involved in fibrosis/excessive
extracellular matrix accumulation
Fibrillin 1
Tan et al., in an extension of their previous work on fibrillin
1 [10], reported that a single-nucleotide polymorphism in
the 5′-untranslated region of FBN1 was strongly associ-
ated with SSc in Choctaw Indians (who have a very high
prevalence of SSc) and that the two haplotypes in
Choctaws containing this polymorphism have associations
with SSc in Japanese patients [11]. FBN1 had been
chosen as a candidate gene because it mapped to the
region of linkage on chromosome 15q identified in the
earlier study and because of the duplication of FBN1 gene
in the tsk1 mouse.
COL1A2
Hata et al. reported the association with SSc of a specific
combination of functional dinucleotide repeats (13,6,8)-12
in the human type-I-collagen α2 chain (COL1A2) gene,
especially in male patients with disease-specific autoanti-
bodies [12].
Transforming growth factor-β (TGF-β)
TGF-β1 has been implicated in the pathogenesis of
fibrosis and its expression is increased in scleroderma-
tous skin. It therefore seems an obvious candidate gene.
However, Zhou et al., using microsatellites and intra-
genic markers, found no significant associations
between TGF-β1, TGF-β receptors I and II, latent TGF-
β1-binding protein, platelet-derived growth factors A and
B (and their receptors), and SSc in Choctaw Indians;
although one microsatellite near the TGF-β1 receptor I
showed a difference in allele frequency between SSc
patients and controls, this result was thought to be a
false positive [13]. Similarly, we found no association
between SSc and microsatellite markers for TGF-β1 or
for platelet-derived growth factor B, but we did find
associations between SSc and markers for TGF-β3,
TGF-β2, and (in males only) tissue inhibitor of metallo-proteinase-1 [14]. The TGF-β associations were depen-
dent on disease subtype: limited cutaneous disease was
associated with TGF-β2 and diffuse cutaneous disease,
with TGF-β3 [14].
Genes implicated in pulmonary fibrosis
The most life-threatening aspect of excessive fibrosis is
fibrosing alveolitis. Investigators have recently reported
polymorphisms in the fibronectin gene in SSc-related pul-
monary fibrosis [15]. The same investigators went on to
examine polymorphisms of the IL-8 and IL-8-receptor
genes CXCR1 (IL8RA) and CXCR2 (IL8RB) in patients
with SSc (subclassified as those with and those without
fibrosing alveolitis), in patients with cryptogenic fibrosing
alveolitis, and in healthy control subjects: while there was
an association between SSc and two polymorphisms of
the CXCR2 gene, this association was independent of the
presence or absence of fibrosing alveolitis [16].
Genes primarily involved in vascular function and
structure
The recent developments in the genetics of pulmonary
arterial hypertension have been of considerable interest to
those with an interest in SSc [17]. Mutations in the gene
for bone morphogenetic protein receptor II, a member of
the TGF-β-receptor family, have been identified in patients
with familial primary pulmonary hypertension [18], and
mutations in activin-receptor-like kinase I, a TGF-β recep-
tor, have been identified in patients with pulmonary arterial
hypertension associated with the inherited disease heredi-
tary haemorrhagic telangiectasia [19]. Elucidation of the
molecular mechanisms by which these mutations lead to
pulmonary vascular change may provide new insights into
the pathophysiology of SSc as well as of pulmonary arter-
ial hypertension.
Genes involved in autoimmunity
There have been many studies investigating genes for
human leukocyte antigen (HLA) in patients with SSc:
several HLA genes have been weakly associated with SSc
in different ethnic groups. Much stronger associations,
however, have been observed with specific autoantibodies
and/or disease subsets (reviewed by Tan and Arnett [20]).
For example, anticentromere antibodies have been associ-
ated with HLA-DQB1 alleles [21], and antitopoisomerase
antibodies, with an HLA-DRw11 allele as well as with a
particular HLA-DQB1 sequence [22]. Anti-Th/To antibod-
ies have also been associated with HLA-DR11, as well as
with a reduced frequency of HLA-DR7, this latter associa-
tion found also in patients with anti-centromere antibodies
[23]. These immunogenetic associations are thought to
reflect T-cell involvement in autoimmunity.
One of the most interesting novel hypotheses to be inves-
tigated in recent years is that SSc might result from a
graft-versus-host reaction as a result of retained and per-
sistent fetal cells in mothers — so-called microchimerism.
This concept can be expanded to explain SSc in males, as
the exchange of cells at birth can be two-way. The investi-
gation of this hypothesis is technically difficult, because
PCR contamination must be completely avoided. Both
HLA and Y-chromosome sequences have been investi-
gated, but from the results to date it is difficult to conclude
that this concept is specific to SSc [24,25]. This recent
interest in microchimerism in the pathogenesis of SSc has
extended to its link with HLA. Lambert et al. reported that
persistent fetal microchimerism (in both healthy women
and those with SSc) is associated with DQA1*0501 [26]
and that this allele is associated with SSc in male patients
[27]. These observations suggest that HLA may confer
susceptibility to SSc via many different mechansims.
Finally, on autoimmunity and the immune response, tumour
necrosis factor (TNF) has recently received considerable
interest, because its actions can be blocked therapeuti-
cally. While an association between the microsatellite
TNF-α13 and SSc has recently been reported in Japanese
patients, the fact that TNF alleles are in linkage disequilib-
rium with HLA class II alleles reduced the importance of
this association [28].
Conclusion
Evidence is accumulating that genetic susceptibility plays
a role in the pathogenesis of SSc. However, the situation
is highly complex and association studies suggest that
susceptibility may be determined by a number of different
genes, with different genes interacting to produce a phe-
notype that is predominantly fibrotic or is predominantly
associated with vascular abnormality, depending upon the
patient’s disease subtype. With the advent of new tech-
nologies, our ability to look for genetic abnormalities in dif-
ferent clinical and serological subgroups of patients, and
the functional correlates of these, is rapidly expanding.
The combination of developments in microarray technol-
ogy and knowledge of the human genome will ultimately
mean that the gene-expression profiles of cells will be inti-
mately mapped and thus potential disease genes and
pathways will be identified for genetic investigation and
perhaps, ultimately, therapeutic intervention. This
approach will be ideal for comparing processes in clini-
cally affected and unaffected skin from SSc patients; in an
early application of this technology, Feghali and Wright
found that many RNAs, including fibronectin, were differ-
entially expressed in sclerodermatous skin [29]. Such
experiments require careful interpretation and there is also
growing evidence that it will be necessary to study expres-
sion at the protein rather than the RNA level, because the
two are not necessarily correlated. Understanding more
about gene regulation and gene expression in different
tissues, and thus about genetic susceptibility, will help us
to unravel the pathophysiology of this complex and fasci-
nating disease process.
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